ArticleFrontiers in genetics2025
Gene expression profiling of SPIN1 in gastric cancer: insights into tumorigenesis and potential therapeutic targets.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating multiple omics and machine learning to reveal the prognostic value of endoplasmic reticulum stress geneTranslational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is a prevalent malignant tumor globally, posing a significant threat to human health. The histone code reader Spindlin1 (SPIN1) has been implicated in tumorigenesis and tumor progression, however, the exact molecular mechanisms underlying these processes remain incompletely understood. The biological function and regulatory mechanisms of SPIN1 in GC remain ambiguous. This study aims to investigate the regulatory mechanisms of SPIN1 in the pathogenesis and progression of GC, as well as to identify genes closely associated with SPIN1 and potential biomarkers. Methods: Gene expression profiles from 375 patients diagnosed with gastric cancer (GC) and 32 control subjects were obtained from the TCGA-STAD database. Our study examined the relationships between SPIN1 expression and various factors including tumor progression, clinical stage, survival status, immune microenvironment and drug sensitivity within the cohort of 375 GC patients and 32 controls. Furthermore, we investigated the interplay between m6A and 5 mC regulators in influencing the expression of SPIN1 in GC, and identified genes with significant correlations with SPIN1 through Spearman correlation analysis. Results: A significantly elevated expression of SPIN1 was found in 375 GC patients compared to 32 control subjects. SPIN1 expression was positively correlated with EMT score and angiogenesis score. Cell proliferation-related gene sets (myogenesis, mitotic spindle and G2M checkpoint) were all significantly associated with the high SPIN1 GC group. Eosinophils was associated with high expression of SPIN1. A total of 21 checkpoints were associated with SPIN1 expression. Low SPIN1 expression group could benefit from Axitinib, Cytarabine, Pazopanib and Sunitinib. Most m6A regulators and a subset of m5C regulators were positively associated with SPIN1. Finally, we screened the 10 genes with the strongest correlation with SPIN1, among which CDH11 and SLC8A1 were associated with the prognosis of GC. Conclusion: In conclusion, our study has provided valuable insights into the pivotal role of SPIN1 in GC development, elucidating its potential molecular mechanisms and establishing it as a promising therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.